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Abstract
Purpose: The development of tools for the analysis of microRNA (miRNA) function in tumors can
advance our diagnostic and prognostic capabilities. Here, we describe the development of
technology for the profiling of miRNA expression in the tumors of live animals.
Procedures: The approach is based on miRNA nanosensors consisting of sensor oligonucle-
otides conjugated to magnetic nanoparticles for systemic delivery. Feasibility was demonstrated
for the detection of miR-10b, implicated in epithelial to mesenchymal transition and the
development of metastasis. The miR-10b nanosensor was tested in vivo in two mouse models of
cancer. In the first model, mice were implanted subcutaneously with MDA-MB-231-luc-D3H2LN
tumors, in which miR-10b was inhibited. In the second model, mice were implanted bilaterally
with metastatic MDA-MB-231 and nonmetastatic MCF-7 cells. The nanosensors were injected
intravenously, and fluorescence intensity in the tumors was monitored over time.
Results: We showed that the described nanosensors are capable of discriminating between
tumors based on their expression of miR-10b. Radiant efficiency was higher in the miR-10b-
active tumors than in the miR-10b-inhibited tumors and in the MDA-MB-231 tumors relative to
the MCF-7 tumors.
Conclusions: The described technology provides an important tool that could be used to answer
questions about microRNA function in cancer.
Key words: Nanosensors, miRNA, Oligonucleotides, Activatable probes, Fluorescence,
Magnetic nanoparticles, Cancer, Metastasis
Introduction
A s reported by Ling et al. [1], during the past decade,over 25,000 papers deposited on PubMed have
reported on various aspects of microRNA (miRNA) geno-
mics, biogenesis, mechanisms of action, pathway involve-
ment, phenotypes in experimental models, and disease
abnormalities. About 40 % of these publications have
focused on the role of miRNAs in cancer. These studies
have shown that miRNAs are dysregulated in almost all
types of human cancer and specific signatures of aberrantly
expressed miRNAs harbor diagnostic, prognostic, and
therapeutic implications, including early diagnosis and
staging, discrimination between different types of cancer,
the identification of the tissue of origin of poorly differen-
tiated tumors, prediction of chemotherapeutic response, etc.
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These are all challenges that are still largely unresolved and
the subject of intense clinical interest [1].
The overwhelming evidence in the literature of the value
of miRNAs as cancer biomarkers underscores the impor-
tance of developing tools to understand how miRNAs
participate in key aspects of carcinogenesis. Here, we
describe technology that provides this capability in an
in vivo setting. Specifically, we have developed nanosensors
based on fluorescent turn-on oligonucleotide probes (oligos)
sensitive to individual microRNA-mediated RNA interfer-
ence [2]. The nanosensors consist of dextran-coated
aminated iron oxide magnetic nanoparticles (MNs, 25–
30 nm in diameter), conjugated to sensor oligos that are
perfectly complementary to endogenous miRNA species. It
is well known now that the choice between messenger RNA
(mRNA) degradation and translational repression is depen-
dent on the degree of complementarity between the mRNA
target and the miRNA seed region [3]. Earlier, we had
hypothesized and then confirmed [2] that sensor oligonucle-
otides perfectly complementary around the miRNA seed
region would be cleaved in a sequence-specific way by the
microRNA-RNA-induced silencing complex (RISC). In this
work, we showed that a perfectly complementary sensor
oligonucleotide specific to miR-10b is cleaved by miR-10b-
RISC, despite the fact that all of miR-10b’s known mRNA
targets are bound with imperfect complementarity and
regulated by translational repression and not mRNA cleav-
age. The sensor oligonucleotides are labeled with a
fluorescent dye-quencher pair, so that upon cleavage of the
oligonucleotide by the microRNA-RISC, fluorescence en-
hancement is observed.
We believe that the nanosensors have significant advan-
tages over current technology. The currently established
methods for microRNA detection in situ rely on PCR and
northern blotting or high-affinity hybridization probes [4–
14]. However, these methods are only applicable in vitro.
Consequently, they do not permit longitudinal studies, in
which the Bevolution^ of the tumor cell phenotype is
monitored in an intact physiologic environment. In contrast,
our approach offers the possibility for in vivo detection and
monitoring. In addition, the existing methods rely on direct
hybridization of the sensor oligo to the miRNA, reflecting a
1:1 ratio of fluorescent probe per miRNA. By contrast, our
approach employs a powerful signal amplification strategy.
Namely, consistent with our experience [15], each cell in
this study is estimated to take up over 1×106 nanoparticles
with attached sensor oligos. Each miRNA-RISC cleaves its
complementary substrate oligo catalytically, leading to
powerful signal amplification resulting from the cleavage
of millions of synthetic substrates on the nanoparticles by
the cognate miRNA-RISC complex [16, 17]. Finally, the
described method, unlike approaches that rely on biolumi-
nescent or fluorescent reporter gene expression [18–21], is
composed of simple synthetic components that would one
day make clinical applications more feasible. Also, unlike
hybridization probes (e.g., molecular beacons and
SmartFlare, Millipore) the nanosensor does not remain
stably bound to the miRNA and does not interfere with
cellular function [2].
In the current study, we demonstrate the feasibility of the
approach by focusing on miRNA-10b. miR-10b has been
implicated in epithelial to mesenchymal transition and breast
cancer metastasis by multiple studies including by our own
group [22, 23–25]. Consequently, it is an attractive target
with preclinical and clinical significance. Still, the technol-
ogy can be utilized to measure the expression of any miRNA
in any solid tumor model to answer questions related to
cancer epigenetics. For example, it can be applied for
monitoring the expression of microRNAs implicated in
cancer progression and can be utilized in preclinical drug
development. In particular, since microRNAs represent
highly specific and/or early predictive biomarkers of
metastatic potential, the technology could be used to gather
information that could aid in forecasting invasive disease
and predicting response to specific therapeutic modalities,
leading to the design of individualized treatments. Clinically,
the described technology could one day be used as a
diagnostic and/or prognostic tool and support monitoring
of treatment response [26–28].
Materials and Methods
Sensor Oligonucleotide
The sensor oligonucleotide (5′-5ThioMC6D/UUU/Cy5/CACAAA
UUCGGUUCUACAGGGUA/IAbRQSp-3′) was designed to be
perfectly complementary to the target miRNA, miRNA-10b, which
plays a key role in epithelial-mesenchymal transition [23]. The
backbone of the sensor oligonucleotide was composed of natural
RNA bases. The 5′-end of the sequence was modified with Cy5
(fluorescent dye) and a spacer with three nucleic acids, which had a
Thio-MC6-protected thiol group for the conjugation to MNs. Iowa
Black RQ (quencher) was placed at the 3′-end of the sensor
oligonucleotide. The oligo was synthesized by Integrated DNA
Technologies (Coralville, IA).
Synthesis of Dextran-Coated MNs
MN was synthesized following a protocol published previously
[22]. Briefly, 30 ml of Dextan-T10 (0.3 g/ml, Pharmacosmos A/S,
Holbaek, Denmark) was mixed with 1 ml of FeCl3·6H2O (0.65 g/
ml, Sigma, Saint Louis, MO) while flushing argon gas for an hour.
One milliliter of FeCl2·4H2O (0.4 g/ml, Sigma) was added to the
mixture, and 15 ml of cold NH4OH (28 %, Sigma) was added
dropwise to the stirred mixture. The temperature was increased to
85 °C for 1 h to start the formation of a nanoparticle dispersion and
then cooled to room temperature. The magnetic nanoparticles were
concentrated to 20 ml using Amicon ultra centrifugal units (MWCO
30 kDa; Millipore, Darmstadt, Germany). The resulting dextran-
coated magnetic nanoparticles were cross-linked by epichlorohy-
drin (14 ml, 8 h, Sigma) and aminated with subsequent addition of
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NH4OH (28 %, 60 ml). Aminated MNs were purified by dialysis
and concentrated using Amicon ultra centrifugal units.
MN properties were as follows: Iron concentration was
10.94 mg/ml as determined using Total Iron Reagent Set (Pointe
Scientific, Canton, MI); each nanoparticle contained 74 amine
groups as determined by the N-succinimidyl 3-[2-pyridyldithio]-
propionate (SPDP) quantification method; the size of MN was 20.3
±0.6 nm as determined by dynamic light scattering (Zetasizer Nano
ZS, Malvern Instruments Ltd., Westborough, MA).
Synthesis and Characterization of MN-miR-10b
Nanosensor
MN was sequentially conjugated to the heterobifunctional linker
SPDP (Thermoscientific Co., Rockford, IL) and activated oligonu-
cleotides. Briefly, 7.5 mg of SPDP was dissolved in 25 μl of
anhydrous DMSO and incubated with MN, which has a maleimide
group for thioether linkage with activated oligonucleotides. To
release the thiol from the 5′-ThioMC6 linker and activate the
oligonucleotides for conjugation, we used 3 % Tris(2-
chloroethyl)phosphate (TCEP) treatment in nuclease-free phos-
phate-buffered saline (PBS). Activated oligonucleotides were
purified using an ammonium acetate/ethanol precipitation method.
After TCEP activation and purification, activated oligonucleotides
were dissolved in nuclease-free water and incubated with the
SPDP-modified MN overnight. The MN-miR-10b nanosensor was
purified from unconjugated sensor oligonucleotide using a mag-
netic column (MACS 20 μ column, Miltenyi Biotech Inc., San
Diego, CA).
The MN-miR-10b nanosensor was freshly prepared before each
injection, and the number of oligonucleotides per MN was
estimated as 3.0 by electrophoresis as described previously [22,
29]. The final size of the MN-miR-10b nanosensor was 22.2
±0.3 nm.
Cells
The human breast cancer cell line, MDA-MB-231-luc-D3H2LN,
was purchased from Perkin Elmer (Hopkinton, MA) and cultured in
Dulbecco’s modified Eagle’s medium (Sigma, Saint Louise, MO)
supplemented with 10 % fetal bovine serum (FBS) (Thermo
Scientific, Waltham, MA), 1 % antibiotics (Invitrogen, Carlsbad,
CA), and 2 mM L-glutamine. The human breast cancer cell line
MCF-7 was purchased from ATCC and cultured in RPMI 1640
medium with 5 % FBS and 1 % antibiotics, per the supplier’s
instructions (ATCC, Manassas, VA).
Fluorescence Activation by Nuclease A
To test fluorescence activation of the synthesized nanosensor, we
incubated it with specific nuclease.
Five microliters of purified nanosensor solution (10 μg Fe,
400 pmol as sensor oligo) was mixed with 92 μl of PBS buffer in a
96-well plate. The plate was read one time before the addition of
3 μl nuclease A (10 mg/ml, 700 U/ml, Qiagen, Hilden, Germany).
The reading was repeated according to a prefixed schedule to
obtain the maximum fluorescence activation after the addition of
nuclease A. The fluorescence spectra were collected using the
following parameters: excitation wavelength—600 nm, emission
wavelength—640–800, cutoff—630 nm, interval—2 nm, acquisi-
tion number—6.
Animal Model
The miR-10b-inhibited tumor model was generated as described in
[22]. Briefly, six-week-old female old nude mice (n=5) were
implanted subcutaneously with MDA-MB-231-luc-D3H2LN cells
(2×106 cells in the right flank). When tumors reached a diameter of
~0.5 cm, the animals were injected intravenously with a miR-10b
inhibitor (MN-anti-miR-10b, nanoparticles carrying locked nucleic
acid binding to miR10-b) or an inactive control (MN-scr-miR,
nanoparticles carrying irrelevant locked nucleic acid) to generate
the miR-10b inhibited group or active group, respectively. This
treatment leads to complete inhibition of miR10-b as we have
shown in our previous work [22].
For the bilateral tumor model, six-week-old female athymic
nude mice (n=5) were treated with estradiol cypionate (3 mg/kg) in
cottonseed oil for 2 weeks and implanted subcutaneously in the
flanks with MDA-MB-231-luc-D3H2LN (2×106 cells) and MCF-7
(2×106 cells). All animal experiments were performed in compli-
ance with institutional guidelines and approved by the Institutional
Animal Care and Use Committee (IACUC) at Massachusetts
General Hospital.
Fluorescence/Bioluminescence Optical Imaging
Imaging was performed using the IVIS Spectrum imaging system
(Perkin Elmer, Hopkinton, MA). Anesthetized mice were intrave-
nously injected with MN-miR-10b nanosensor (15 mg/kg Fe;
1.7 mg/kg sensor oilgo) and scanned 1, 3, 5, 7, 9, 11, 13, 18, 24,
and 40 h after injection. The acquisition conditions for fluorescence
imaging were as follows: exposure time—0.5 s; binning factor—8;
excitation filter range—570, 605, 640, and 675 nm; emission filter
range—640, 660, 680, 700, and 720 nm; f number—2. Spectral
unmixing (Living Image ver. 4.4) was employed to minimize the
influence of tissue autofluorescence. Radiant efficiency was
measured for the same region of interest (ROI) in all images. At
the end of the fluorescence imaging session, mice were injected
intraperitoneally with D-luciferin potassium salt in DPBS (200 μl
of 15 mg/ml; Perkin Elmer, Hopkinton, MA). Identical imaging
acquisition settings (time, 0.5~60 s; F-stop—2; binning—medium)
and the same regions of interest (ROIs) were used to obtain total
radiance (photons/s/cm2/sr) from the tumors.
Real-Time Quantitative Reverse Transcription-
PCR
Surgically removed primary tumor tissues were homogenized to
extract the miRNA-enriched fraction. Relative levels of miR-10b
were determined by real-time quantitative reverse transcription-
PCR (qRT-PCR; Taqman protocol) and compared to the internal
housekeeping gene, SNORD44. Taqman analysis was carried out
using an ABI Prism 7700 sequence detection system (Applied
Biosystems, Foster City, CA). The primers (Hs-miR-10b-3
miScript Primer, Hs-SNORD44-11 miScript Primer) and assay kit
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(miScript PCR Starter Kit) were purchased from Qiagen. Relative
expression was calculated by the ΔΔCt method.
Fluorescence Microscopy of Tissue Sections
Excised tumor tissues were embedded in Tissue-Tek OCT
compound (Sakura Finetek, Torrance, CA) and snap frozen in
liquid nitrogen. The tissues were cut into 7-μm sections. The slides
were counterstained and mounted with Vectashield mounting
medium with (4′,6-diamidino-2-phenylindole (DAPI) (Vector Lab-
oratories, Inc. Burlingame, CA). To determine MN-miR-10b
accumulation in tissue, the sections were analyzed by fluorescence
microscopy using a Nikon Eclipse 50i fluorescence microscope
(Nikon, Tokyo, Japan), equipped with the necessary filter sets
(Chroma Technology Corporation, Bellows Falls, VT). Images
were acquired using a charge-coupled device camera with near-IR
sensitivity (SPOT 7.4 Slider RTKE; Diagnostic Instruments,
Sterling Heights, MI). The images were analyzed using SPOT 4.0
Advance version software (Diagnostic Instruments, Sterling
Heights, MI).
Statistical Analysis
Data were expressed as mean±SD. Statistical comparisons were
drawn using a two-tailed t test (SigmaStat 3.0; Systat Software,
Richmond, CA). A value of pG0.05 was considered statistically
significant.
Results
General Design and Mechanism
The design of the MN-miRNA nanosensor is based on our
prior publications [30, 31] [22] in which we have described
the development and application of oligonucleotide-
modified nanoparticles for the targeting of the RNAi
mechanism in tumor cells. Specifically, the nanosensor
consists of MNs (~20 nm in diameter), conjugated to sensor
oligos [2] that are perfectly complementary to endogenous
miRNA species (Fig. 1a). The design and testing of the
prototype sensor oligos have recently been described by us
[2]. Specifically, the sensor oligonucleotides are composed
of RNA bases and are cleavable (nonstabilized by chemical
modification) around the seed region (the conserved region
within which the microRNA engages the RNA substrate).
The oligonucleotide strand is labeled with a fluorescent dye-
quencher pair, so that upon its cleavage by the microRNA-
RISC, the dye-quencher pair separates resulting in
dequenching and fluorescence enhancement (Fig. 1a). In
our prior study, we demonstrated the feasibility of accurately
detecting miRNA expression in a cell-free system and intact
cells in vitro using the described sensor oligonucleotide
design and extensively validated our hypothesis that fluo-
rescence enhancement resulted from specific cleavage of the
sensor oligo by the miR-primed RISC [2].
For in vivo delivery, the oligo was conjugated to the
nanoparticles. Nanosensor accumulation in the tumor is
driven by the innate pathways of hemodynamics and
biodistribution characteristic for the nanoparticles and
governed by the well-established enhanced permeability
and retention (EPR) effect, as indicated by our earlier work
[29, 30]. The specific mechanism of nanosensor action is
described in Fig. 1b. Namely, following intravenous injec-
tion, the long-circulating nanoparticles distribute through the
circulation and progressively accumulate in the tumor
interstitium due to its hyperpermeable vasculature and
compromised lymphatic drainage (EPR effect) [32]. Once
inside the tumor interstitium, the nanoparticles are
endocytosed by the tumor cells through macropinocytosis
Fig. 1 Nanosensor design and mechanism of action. a The nanosensor consists of magnetic nanoparticles (MNs), conjugated
to sensor oligos that are perfectly complementary to endogenous miRNA species. These sensor oligonucleotides are
composed of RNA bases and are cleavable (nonstabilized by chemical modification) around the seed region (the conserved
region within which the microRNA engages the RNA substrate). The oligonucleotide strand is labeled with a fluorescent dye-
quencher pair, so that upon its cleavage by the microRNA-RISC, the dye-quencher pair separates producing dequenched
fluorescence enhancement. b In the cytosol, the nanoparticles, which carry a sensor oligo complementary to an endogenous
microRNA species, bind the microRNA, leading to the recruitment to the endogenous RNA-induced silencing complex (RISC)
and cleavage of the oligo at a specific position in the seed region. This cleavage results in separation between the quencher
and dye located at the ends of the sensor oligo and fluorescent turn-on. The microRNA is released from the complex and is free
to catalyze subsequent cleavage reactions.
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and localize to endosomes [29]. Inside endosomes, the
functionalized nanoparticles rich in unsaturated amines
mediate the proton sponge effect leading to endosomal
rupture and nanosensor deposition in the cytosol [33]. In the
cytosol, the nanoparticles, which carry a sensor oligo
complementary to an endogenous microRNA species, bind
the microRNA based on complementarity to its seed region,
leading to the recruitment to the endogenous RISC and
cleavage and degradation of the oligo. This cleavage results
in separation between the quencher and dye located at the
ends of the sensor oligo and fluorescent turn-on. The
microRNA is released from the complex and is free to
catalyze subsequent cleavage reactions [2].
The described mechanism exploits the endogenous
process of RNA interference and takes advantage of
powerful signal amplification. Namely, a single miRNA
will cleave numerous substrate oligos, since RNAi is a
Bcatalytic^ molecular mechanism. In addition, a single
nanoparticle can carry up to 40 substrate oligos, taking
advantage of the phenomenon of multivalency [34, 35].
Finally, the number of nanoparticles taken up by the tumor
cells is large (15×106 nanoparticles/cell) [15].
The MN-miRNA Nanosensor Is Functional
To assess the feasibility of the approach, we designed a
nanosensor that can detect the expression of miRNA-10b.
miR-10b has been implicated in epithelial to mesenchymal
transition and breast cancer metastasis by multiple studies
including by our own group [22, 23–25]. Consequently, the
capacity to detect miR-10b expression in tumor cells can
have an important preclinical and clinical impact.
To demonstrate that the nanosensor was synthesized as
designed and to prove successful incorporation of the sensor
oligonucleotide into the nanosensor, after purification, the
nanosensor was treated with a reducing agent (TCEP).
Electrophoretic analysis confirmed the successful release of
the disulphide-conjugated sensor oligonucleotide from MN
following TCEP treatment. No free sensor oligonucleotide
was detected in the absence of TCEP, indicating that in the
final nanosensor preparation, the sensor oligonucleotides
were conjugated to MN (Fig. 2a).
Having previously established that the sensor oligo can
report on miRNA expression in tumor cells [2], we next set
out to determine if conjugation to the nanoparticle carrier
preserves the functionality of the oligo. Figure 2 illustrates
the activation of the MN-miR-10b nanosensor by nuclease
treatment in vitro. The nanosensor was incubated with
excess RNAse A to simulate the catalytic activation of
sensor oligonucleotide. As a control, the MN-miR-10b
nanosensor was incubated in nuclease-free water. These
results showed an over fourfold increase in fluorescence
after incubation with RNAse A, indicating that conjugation
to the MN carrier does not interfere with sensor oligo
activation (Fig. 2b).
The MN-miRNA Nanosensor Can Report on
miRNA Expression In Vivo
To determine the feasibility of detecting miRNA expression
in vivo, we first generated an animal model in which miR-
10b expression in the tumors was either left active or
inhibited, as described in [22]. We injected the nanosensor
intravenously into tumor-bearing animals and performed
whole-body fluorescence reflectance imaging over a time
course of 0 to 24 h using filters for the Cy5 dye on the
sensor oligo. Bioluminescence imaging (BLI) for the
accurate delineation of viable tumor mass was also
performed.
We observed clear enhancement of the primary tumor,
consistent with cleavage of the sensor oligo, separation of
the Cy5 dye from the quencher, and a fluorescent turn-on
(Fig. 3a). This effect was specific for miR-10b, since in the
animals in which miR-10b was inhibited, the signal
enhancement was significantly lower than in the animals in
which miR-10b was active.
Fig. 2 Activation of fluorescence and the release of the sensor oligonucleotide from the MN-miR-10b nanosensor. a
Electrophoresis confirmed the release of sensor oligonucleotides from MN after TCEP treatment. b Cleavage of the sensor
oligo on the nanosensor by nuclease A leads to a 415 % increase in fluorescence intensity over the background.
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Quantitative assessment of relative radiance efficiency
revealed that the maximal difference between miR-10b-
inhibited and miR-10b-active tumors was achieved 18 h
after nanosensor injection (Fig. 3b, 790±70 % enhancement
at the 18 h time point t test, n=3, pG0.05), despite a lack of
difference in viable tumor mass assessed by BLI. qRT-PCR
confirmed these data demonstrating differential miR-10b
expression between the miR-10b-inhibited and miR-10b-
active tumors (Fig. 3c).
Ex vivo examination of tumor tissues confirmed the
observed differential fluorescence intensity between miR-
10b-inhibited and miR-10b-active tumors and confirmed that
fluorescence in the miR-10b active group associated with
tumor cells (Fig. 3d).
In a more clinically relevant model, we illustrated the
application of the nanosensor in nude mice implanted
bilaterally with the highly invasive MDA-MB-231 and the
noninvasive MCF-7 breast cancer cell lines. After
intravenous injection of the nanosensor, we observed
significantly higher fluorescence in the MDA-MB-231
tumors than the MCF-7 tumors (Fig. 4a), corresponding to
a significant difference in radiant efficiency (Fig. 4b,
63±6 % enhancement at the 15-h time point, t test, n=3,
pG0.05). This difference was most pronounced at 15–24 h
after injection of the nanosensor (Fig. 4a, b) and reflected a
difference in the expression levels of miR-10b between the
invasive MDA-MB-231 and noninvasive MCF-7 tumors
(Fig. 4c). Finally, fluorescence microscopy confirmed the
differential fluorescence between the two tumors and
revealed that the activated oligo resided in the cytosol of
the tumor cells (Fig. 4d).
The in vivo kinetics of the signal is expected. A 15- to 24-
h range represents 1.5–2 blood half-lives of the nanosensor
in mice. Therefore, at the time of maximum fluorescence
intensity, about 25 % of the original injected dose would still
exist in the circulation and would contribute to an increase in
Fig. 3 In vivo detection of miR-10b expression in a miR-10b-inhibited breast tumor model. a Fluorescence optical imaging
showing significantly higher fluorescence intensity in the tumors in which miR-10b was left active over the miR-10b-inhibited
tumors (i.v., 15 mg/kg Fe; 1.7 mg/kg sensor oilgo). Tumor ROIs are color-coded according to radiant efficiency. b Quantification
of radiant efficiency from A indicated a peak of fluorescence activation in the miR-10b-active tumors at 18 h after nanosensor
injection. c qRT-PCR of miR-10b expression in the miR-10b-active vs miR-10b-inhibited tumors demonstrated a significant
difference between the two groups (data represent average±SD; two-tailed t test; n=3). d Fluorescence microscopy of tumor
tissue from mice injected with the nanosensor. Cy5 fluorescence from the activated nanosensor was seen in the miR-10b-
active tumors but not the miR-10b-inhibited tumors (blue—DAPI, nuclei; red—Cy5, activated nanosensor).
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background signal. However, at later time points, the relative
contribution of nanosensor in the tumor circulation vs inside
tumor cells would be reduced due to nanosenser clearance.
At that point, most of the fluorescence signal from tumor
tissues is expected to be coming from activated sensor oligo
inside tumor cells. However, because of a time lag in the
passive delivery of the nanosensor into tumor tissues
through the EPR effect, there would be a longer activation
time in vivo than expected from the kinetics of the RNAi
process.
After dynamic fluorescence signal quantification, the
suggested mechanism of nanosensor activation is as
follows. At the early time points, there is a large amount
of nanosensor in the blood, but the oligo is intact (not
cleaved) and therefore mostly Bdark.^ Consequently, the
changes in fluorescence at these time points would
reflect nanosensor pharmacodynamics (Suppl Figs. 1a
and 2a). At 15–24 h, the nanosensor is localized in
tumor tissues and continuously taken up by cells, leading
to the cleavage (activation) of the oligo. However, at that
time point, the cleavage products have not yet been
exocytosed/cleared, resulting in a dramatic and rapid
increase in fluorescence (Suppl. Figs. 1b and 2b). After
24 h, the cleaved products are secreted by the tumor
cells and cleared through the circulation, leading to a
loss of fluorescence (Suppl. Figs. 1b and 2b). This
hypothesis is consistent with our earlier findings, indi-
cating exocytosis of the oligonucleotide fragments after
cleavage [2].
Discussion
With the goal of gaining a better understanding of the role of
miRNA in cancer and of making miRNA-based diagnostics
possible, we have developed technology for the profiling of
tumor miRNAs in vivo. In these early feasibility studies, the
nanoparticle-conjugated oligo was terminally labeled with
the dye and the quencher. Consequently, the two were
separated by 22 nucleotides (7.5 nm). However, it is possible
to optimize the oligo by introducing internal labels and using
alternative dye-quencher pairs. For example, if we have a
10-nucleotide (nt) distance (3.4 nm) between the dye and
quencher, that would result in a distance of of 3.4 nm
(10×3.4 Å/nucleotide=34 Å=3.4 nm). For the IRDye
700DX-QC-1 pair for example, the expected quenching
efficiency at that distance will be 98.8 % (Li-COR
Biosciences, Lincoln, NE).
In our studies, we demonstrated that the technology
allows for profiling tumor miRNA signatures in vivo. This is
important because it is only through in vivo studies that one
can capture the true dynamics of cancer initiation and
progression. Since the method is completely noninvasive, it
will be possible to collect time-course data in genuine
physiologic environments and thus gain a better understand-
ing of individual-to-individual variation, authentic molecular
processes, and long-term trends.
In a laboratory setting, the tools developed here can lead
to the mapping out of a comprehensive and systematic atlas
of cancer progression. In a clinical setting, the technology
Fig. 4 In vivo detection of miR-10b expression using the nanosensor in mice bilaterally implanted with MDA-MB-231 and
MCF-7 cells. a Fluorescence optical imaging showed differential fluorescence intensity from the two tumors (i.v., 15 mg/kg Fe;
1.7 mg/kg sensor oligo). b Quantification of radiant efficiency showed a peak of differential radiant efficiency at 15–24 h after
nanosensor injection. c qRT-PCR expression demonstrated significantly higher expression of miR-10b in the MDA-MB-231
tumors (data represent average±SD; two-tailed t test; n=3). d Fluorescence microscopy of tumor tissues from MDA-MB-231
and MCF-7 tumors. Cy5 radiant efficiency from the activated nanosensor was higher in the MDA-MB-231 tumors than in the
MCF-7 tumors (blue—DAPI, nuclei; red—Cy5, activated nanosensor).
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will facilitate early cancer detection and/or cancer risk
assessment and facilitate/accelerate the process of drug
discovery.
With specific relevance to clinical application, the
nanocarrier component of the nanosensors is based on a
clinically approved nanoparticle [36, 37]. Consequently, a
derivative of the developed technology may one day become
applicable in a clinical setting and as such has the potential
of advancing our ability to diagnose and treat breast cancer.
A variety of scenarios could benefit from the described
technology. For example, it has been established that miR-
10b is upregulated in the tumors of patients who harbor
metastatic disease, indicating that miR-10b could be used to
diagnose the presence of metastasis or even to forecast
invasive disease [25, 38, 39]. The ability to detect miR-10b
upregulation in the primary tumors by noninvasive or
laparoscopic methods that specifically target a suspected
lesion would be highly clinically beneficial.
miR-10b is also part of a panel of miRNAs that
demonstrate aberrant expression in tissues from patients
with triple negative breast cancer that displays
chemoresistance [40]. In this context, noninvasive or
laparoscopic imaging can help guide therapeutic decisions.
These are just a few examples of how the described
nanosensors could be of preclinical and clinical value.
However, the list of miRNAs implicated in various aspects
of tumorigenesis is poised to expand rapidly over the next
decade. In addition, the knowledge about the precise roles of
each of the roughly 1500 known human miRNAs is
increasingly becoming more focused, as specific targets are
being identified and validated in vitro. Consequently, the
development of similar technologies for miRNA-based
diagnostics will inevitably represent an element of precision
medicine, defined by rational drug design, individualized
intervention, and targeted image-guided delivery of therapy.
Conclusions
Considering that microRNAs represent highly specific and
very early and/or predictive biomarkers of metastatic potential,
risk assessment, prognosis, and treatment response, the
described methodology can help acquire a better understanding
of the epigenetic mechanisms underlying cancer emergence
and progression. This knowledge could ultimately assist in
forecasting invasive disease and predicting response to specific
therapeutic modalities, leading to the design of individualized
curative or even preventive treatments. In the long run, since
magnetic nanoparticles are already in clinical use and the
technology for optical imaging of the breast is gaining clinical
relevance, one can envision a utility for our method in
application to image-guided laparoscopic or intraoperative
diagnostics.
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